Previous 10 | Next 10 |
This real-money portfolio was first introduced to the Seeking Alpha community in December 2015. The portfolio outperformed its benchmark in Q4 2020 and is now outperforming the S&P 500's performance since late-2015. The portfolio was overweight Financials and Industrials headi...
The FDA has delayed the approval for MYL-1402O, a proposed biosimilar by Viatris (VTRS) and India’s Biocon for the cancer therapy, Avastin (bevacizumab)The regulator has cited the need for more time to inspect the manufacturing facility, a part of the standard review process....
You may have been taken by surprise earlier this month when a new pharmaceutical stock landed in your portfolio that you didn't know you bought -- Viatris (NASDAQ: VTRS) . It may seem like a new stock, but it isn't really. Viatris, which was formed of the combination of My...
Patient recruitment in Phase III trial has surpassed 60% Trial is expanded to Israel with first clinical site at Tel Aviv Medical Center NESS ZIONA, Israel, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late clinical stage biopharmaceutical company, today a...
Mercedes or Porsche? Steak or sushi? Two things can both be good but very different. For investors, the best coronavirus stock may depend on who's choosing. Breaking down the pros and cons of Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) reveals two very different compa...
Mylan Wins Summary Judgment in EpiPen® Litigation Brought by Sanofi PR Newswire PITTSBURGH , Dec. 18, 2020 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that the U.S. District Court for the District of Kansas entered summary judgm...
Viatris Inc. Recommends Caution on TRC Capital Corp.'s Attempt to Acquire Shares at a Significant Discount via Mini-Tender Offer PITTSBURGH , Dec. 15, 2020 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) has been notified of an unsolicited "mini-tender" offer by TRC Cap...
Viatris (VTRS) announces additional details on plans of closure, downsizing or divestiture of up to 15 manufacturing facilities globally that are deemed to be no longer viable either due to surplus capacity, challenging market dynamics or a shift in its product portfolio toward more complex p...
Viatris Inc. Announces Additional Details of Previously Disclosed Global Restructuring Initiative PITTSBURGH , Dec. 11, 2020 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced additional details of its previously disclosed multi-year global r...
Viatris Inc. to Present at the J.P. Morgan 39th Annual Healthcare Conference January 14, 2021 and Will Host its Inaugural Investor Day March 1, 2021 PITTSBURGH , Dec. 10, 2020 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will present at the J.P. Morgan 39 th ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-26 12:25:00 ET The late comedian Rodney Dangerfield was famous for his catchphrase, "I don't get no respect." Does Dangerfield's line apply to some stocks today? Absolutely. Three Motley Fool contributors think they've found surprisingly underrated pharmaceutical stocks to b...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / No country can make every medicine people need, and no medicine is made in every country. If a country or region relies on supply only from within their region and they experience a crisis, there is a risk people won't get the medicines they need, w...
NORTHAMPTON, MA / ACCESSWIRE / July 18, 2024 / Viatris is a global healthcare company focused on bringing high-quality medicines to patients through a hybrid approach that bridges the traditional divide between generics and brands, combining the best of both, to more holistically address healthc...